March 3, 2020 / 12:20 PM / in a month

BRIEF-Prevail Therapeutics Provides Clinical Advancement Update On Pr001 For The Treatment Of Parkinson's Disease With GBA1 Mutations

March 3 (Reuters) - Prevail Therapeutics Inc:

* PREVAIL THERAPEUTICS PROVIDES CLINICAL ADVANCEMENT UPDATE ON PR001 FOR THE TREATMENT OF PARKINSON’S DISEASE WITH GBA1 MUTATIONS

* PREVAIL THERAPEUTICS INC - ENROLLMENT IN PR001 PHASE 1/2 PROPEL CLINICAL TRIAL IS PROGRESSING, PATIENT DOSING CONTINUES

* PREVAIL THERAPEUTICS INC - ON TRACK TO REPORT INTERIM DATA ON A SUBSET OF PATIENTS IN H2 2020 FROM PR001 PHASE 1/2 PROPEL CLINICAL TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below